Wall Street brokerages forecast that aTyr Pharma, Inc. (NASDAQ:LIFE) will report earnings per share of ($0.43) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for aTyr Pharma’s earnings. The lowest EPS estimate is ($0.48) and the highest is ($0.39). aTyr Pharma reported earnings of ($0.53) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 18.9%. The business is expected to issue its next quarterly earnings report on Thursday, March 15th.

According to Zacks, analysts expect that aTyr Pharma will report full year earnings of ($1.93) per share for the current fiscal year, with EPS estimates ranging from ($1.98) to ($1.88). For the next financial year, analysts anticipate that the firm will report earnings of ($1.91) per share, with EPS estimates ranging from ($2.31) to ($1.37). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for aTyr Pharma.

How to Become a New Pot Stock Millionaire

aTyr Pharma (NASDAQ:LIFE) last announced its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.07.

Several analysts recently issued reports on the stock. ValuEngine cut shares of aTyr Pharma from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Zacks Investment Research raised shares of aTyr Pharma from a “hold” rating to a “buy” rating and set a $4.25 target price on the stock in a report on Saturday, November 18th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company. aTyr Pharma has a consensus rating of “Hold” and an average target price of $4.81.

Several large investors have recently modified their holdings of the business. Dimensional Fund Advisors LP raised its holdings in shares of aTyr Pharma by 44.1% during the third quarter. Dimensional Fund Advisors LP now owns 83,848 shares of the biotechnology company’s stock worth $423,000 after purchasing an additional 25,676 shares during the period. Victory Capital Management Inc. acquired a new stake in shares of aTyr Pharma in the 3rd quarter worth about $455,000. Finally, Artal Group S.A. acquired a new stake in shares of aTyr Pharma in the 3rd quarter worth about $1,263,000. 58.28% of the stock is currently owned by institutional investors.

aTyr Pharma (NASDAQ LIFE) traded up $0.10 on Friday, reaching $3.85. 7,556 shares of the company traded hands, compared to its average volume of 38,493. The firm has a market capitalization of $114.57, a PE ratio of -1.90 and a beta of 3.83. The company has a quick ratio of 9.49, a current ratio of 9.49 and a debt-to-equity ratio of 0.17. aTyr Pharma has a 1 year low of $2.30 and a 1 year high of $6.50.

COPYRIGHT VIOLATION WARNING: “Brokerages Anticipate aTyr Pharma, Inc. (LIFE) to Post -$0.43 Earnings Per Share” was first posted by Marea Informative and is owned by of Marea Informative. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://www.mareainformativa.com/2018/01/30/brokerages-anticipate-atyr-pharma-inc-life-to-post-0-43-earnings-per-share-updated-updated-updated.html.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Get a free copy of the Zacks research report on aTyr Pharma (LIFE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.